Atomoxetine in the treatment of psychostimulant-naive children and adolescents with ADHD: a 6-week, randomized, placebo-controlled trial in Russia

被引：1
|
作者：
Martenyi, F.
Zavadenko, N.
Jarkova, N.
机构：
[1] Eli Lilly Ges MBH, Lilly Res Labs, Vienna, Austria
[2] Russian State Med Univ, Minist Hlth, Chile Neurol Dept, Moscow 117437, Russia
[3] Eli Lilly Vostok SA, Lilly Res Labs, Moscow, Russia
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2006年 / 16卷
关键词：
D O I：
10.1016/S0924-977X(06)70730-1
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S527 / S528
页数：2
相关论文
共 50 条
  • [1] Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia
    Ferenc Martenyi
    Nikolay N. Zavadenko
    Natalia B. Jarkova
    Alexandr A. Yarosh
    Victoria O. Soldatenkova
    Leonid M. Bardenstein
    Irina A. Kozlova
    Nikolay G. Neznanov
    Olga I. Maslova
    Andrey S. Petrukhin
    Nina K. Sukchotina
    Valeriy P. Zykov
    [J]. European Child & Adolescent Psychiatry, 2010, 19 : 57 - 66
  • [2] Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia
    Martenyi, Ferenc
    Zavadenko, Nikolay N.
    Jarkova, Natalia B.
    Yarosh, Alexandr A.
    Soldatenkova, Victoria O.
    Bardenstein, Leonid M.
    Kozlova, Irina A.
    Neznanov, Nikolay G.
    Maslova, Olga I.
    Petrukhin, Andrey S.
    Sukchotina, Nina K.
    Zykov, Valeriy P.
    [J]. EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2010, 19 (01) : 57 - 66
  • [3] Olanzapine Versus Placebo in Adolescents With Schizophrenia: A 6-Week, Randomized, Double-Blind, Placebo-Controlled Trial
    Kryzhanovskaya, Ludmila
    Schulz, S. Charles
    McDougle, Christopher
    Frazier, Jean
    Dittmann, Ralf
    Robertson-Plouch, Carol
    Bauer, Theresa
    Xu, Wen
    Wang, Wei
    Carlson, Janice
    Tohen, Mauricio
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2009, 48 (01): : 60 - 70
  • [4] Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study
    Goldman, Robert
    Loebel, Antony
    Cucchiaro, Josephine
    Deng, Ling
    Findling, Robert L.
    [J]. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2017, 27 (06) : 516 - 525
  • [5] An 8-Week, Randomized Controlled Trial of Atomoxetine, Atomoxetine Plus Buspirone, or Placebo in Adults With ADHD
    Sutherland, Suzanne M.
    Adler, Lenard A.
    Chen, Crystal
    Smith, Michael D.
    Feltner, Douglas E.
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2012, 73 (04) : 445 - 450
  • [6] Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study
    Ogasa, Masaaki
    Kimura, Tatsuya
    Nakamura, Mitsutaka
    Guarino, John
    [J]. PSYCHOPHARMACOLOGY, 2013, 225 (03) : 519 - 530
  • [7] Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study
    Masaaki Ogasa
    Tatsuya Kimura
    Mitsutaka Nakamura
    John Guarino
    [J]. Psychopharmacology, 2013, 225 : 519 - 530
  • [8] EFFICACY OF LURASIDONE IN ANTIPSYCHOTIC-NAIVE ADOLESCENTS WITH SCHIZOPHRENIA: POST-HOC ANALYSIS OF A 6-WEEK, RANDOMIZED, PLACEBO-CONTROLLED STUDY
    Correll, Christoph
    Goldman, Robert
    Tocco, Michael
    Pikalov, Andrei
    Hsu, Jay
    Loebel, Antony
    [J]. SCHIZOPHRENIA BULLETIN, 2019, 45 : S293 - S294
  • [9] Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study
    Saito, Takuya
    Sugimoto, Saori
    Sakaguchi, Reiko
    Nakamura, Hiroshi
    Ishigooka, Jun
    [J]. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2022, 32 (01) : 12 - 23
  • [10] Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies
    Michelson, D
    Adler, L
    Spencer, T
    Reimherr, FW
    West, SA
    Allen, AJ
    Kelsey, D
    Wernicke, J
    Dietrich, A
    Milton, D
    [J]. BIOLOGICAL PSYCHIATRY, 2003, 53 (02) : 112 - 120
12345